Fundraising Fox
Celldex Therapeutics, Inc.
NASDAQ: CLDXHampton, US · Delaware corporation · 1 known investors
Find your way into Celldex Therapeutics, Inc.
Sign up to find every way you can get introduced to Celldex Therapeutics, Inc.
- Your email: who you already know at Celldex Therapeutics, Inc., and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Celldex Therapeutics, Inc. team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Celldex is a biotechnology company developing therapeutics across therapeutic areas including immunology and inflammation. The page shown is a board director biography rather than a company overview.
Founders & leadership
Board
RV
Richard van den BroekBoard director
TM
Timothy M. Shannon, M. D.Board director
HJ
Herbert J. ConradBoard director
KS
Karen ShoosBoard director
LE
Larry EllbergerBoard director
GO
George O. ElstonBoard director
HH
Harry H. Penner, Jr.Board director
Investors · 1
Funding
SEC filings, press & company announcements$409.5M disclosed across 3 rounds · 2014–2026
- $345MraisedApr 2026 · 2 sourcesSource ↗
▶$62.5MraisedNov 2016 · 29 investors · BiotechnologyRule 506(b)
▶$62.5MraisedNov 2016 · 29 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Herbert J. ConradDirector
- Anthony S. MarucciExecutive Officer, Director
- Karen ShoosDirector
- Richard van den BroekDirector
- Larry EllbergerDirector
- Avery W. CatlinExecutive Officer
- George O. ElstonDirector
- Harry H. Penner, Jr.Director
- Offering amount
- $62.5M
- Amount sold
- $62.5M
- First sale
- Nov 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedOct 2014 · 1 investors · BiotechnologyRule 506(b)
▶$2MraisedOct 2014 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Karen ShoosDirector
- George O. ElstonDirector
- Herbert J. ConradDirector
- Avery W. CatlinExecutive Officer
- Harry H. Penner, Jr.Director
- Timothy M. Shannon, M. D.Director
- Anthony S. MarucciExecutive Officer, Director
- Larry EllbergerDirector
- Offering amount
- $2M
- Amount sold
- $2M
- First sale
- Oct 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
ExelixisExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
Kite PharmaKite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells. The company focuses on cell therapy treatments for cancers such as diffuse large B-cell lymphoma.
Companies working in the same space as Celldex Therapeutics, Inc..
Frequently asked questions
- What does Celldex Therapeutics, Inc. do?
- Celldex is a biotechnology company developing therapeutics across therapeutic areas including immunology and inflammation. The page shown is a board director biography rather than a company overview.
- Who founded Celldex Therapeutics, Inc.?
- Celldex Therapeutics, Inc. was founded by Anthony S. Marucci.
- Who are Celldex Therapeutics, Inc.'s investors?
- Celldex Therapeutics, Inc.'s investors include Foresite Capital.
- How much funding has Celldex Therapeutics, Inc. raised?
- Celldex Therapeutics, Inc. has disclosed $409.5M raised across 3 rounds.
- Where is Celldex Therapeutics, Inc. headquartered?
- Celldex Therapeutics, Inc. is headquartered in Hampton, US.